ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
Anaplastic lymphoma kinase (ALK) rearrangement is usually observed in patients with adenocarcinoma. Herein, we report a case of squamous cell carcinoma (SCC) with ALK rearrangement treated with alectinib. The patient was a 73-year-old woman without a smoking history. She consulted us with nonproduct...
Saved in:
| Main Authors: | Ray Sagawa, Takehiko Ohba, Eisaku Ito, Susumu Isogai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Oncological Medicine |
| Online Access: | http://dx.doi.org/10.1155/2018/4172721 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
by: Hiroshi Hashimoto, et al.
Published: (2022-04-01) -
Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma
by: Julian Verran, et al.
Published: (2022-01-01) -
Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
by: Naoko Imanishi, et al.
Published: (2018-03-01) -
Case Report: Locally advanced lung adenocarcinoma with a novel MIR217HG-ALK rearrangement responding to neoadjuvant alectinib
by: Yinyin Xue, et al.
Published: (2025-08-01) -
Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study
by: A. S. Kolbin, et al.
Published: (2023-11-01)